Clincial Study Patient Recruitment and Site Engagement

The PROSPECT study was a randomized, double-blind, Phase 3 efficacy study of an investigational vaccine (PROSTVAC) ± GM-CSF in men with metastatic, castrate-resistant prostate cancer (mCRPC). Administered during seven treatment visits over five months, these immunizations – delivered by subcutaneous injection along with adjuvant GM-CSF or placebo – were designed to generate immune responses directed against prostate cancer cells.

The investigational vaccine (PROSTVAC) was the result of more than 15 years of poxviral vector development and evaluation. It was a novel candidate prostate cancer immunotherapy for the treatment of prostate cancer – administered subcutaneously during seven treatment visits over five months, along with GM-CSF or placebo.